Ainos (AIMD) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Offering details and pricing
Registration covers up to 6,737,731 shares of common stock for resale by certain selling shareholders, including shares issued under a patent license, special stock awards, warrants, and a purchase and sale agreement.
Shares include 5,500,000 issued to Taiwan Carbon Nano Technology Corporation, 247,500 and 478,000 RSUs granted as special stock awards, 500,000 shares issuable upon warrant exercise, and 12,231 shares issued for an asset acquisition.
Registration is on Form S-3, allowing for delayed or continuous offerings under Rule 415.
Use of proceeds and capital allocation
All estimated offering expenses, including SEC registration, legal, and accounting fees, total approximately $16,965 and are to be paid by the registrant.
Risk factors and disclosures
Indemnification for directors and officers is provided under Texas law and company bylaws, subject to limitations and public policy considerations.
SEC may consider certain indemnification provisions unenforceable as contrary to public policy.
Latest events from Ainos
- AI Nose is scaling as an AI perception platform, targeting industrial and robotics growth in 2026.AIMD
Fireside chat2 Feb 2026 - Secondary offering of 6.7M shares enables liquidity for stockholders, no proceeds to company.AIMD
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification, special stock awards, and meeting adjournment.AIMD
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, special stock awards, and key governance matters.AIMD
Proxy Filing2 Dec 2025 - Votes sought for auditor ratification and 2 million special stock awards at September 2024 meeting.AIMD
Proxy Filing2 Dec 2025 - AI Nose commercialization and cost reductions narrowed Q3 2025 net loss as revenue grew.AIMD
Q3 202513 Nov 2025 - AI Nose rollout drove first revenues, a $2.1M order, and positive gross margin despite wider losses.AIMD
Q2 202513 Aug 2025 - Q2 net loss rose to $3.2M as revenue dropped to zero and drug development accelerated.AIMD
Q2 202413 Jun 2025 - Q3 net loss rose 24% to $3.7M as Ainos pivots from COVID-19 kits to new clinical products.AIMD
Q3 202413 Jun 2025